High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis.

Antibodies, Antinuclear Humans Interferon Type I Lectins, C-Type Lupus Erythematosus, Systemic Lupus Nephritis / pathology Membrane Glycoproteins Receptors, Immunologic
interferon signature gene lupus nephritis podocyte injury type I interferon

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
04 2022
Historique:
accepted: 03 11 2021
pubmed: 17 11 2021
medline: 6 4 2022
entrez: 16 11 2021
Statut: ppublish

Résumé

Previous studies suggest a link between high serum type I interferon (IFN) and lupus nephritis (LN). We determined whether serum IFN activity is associated with subtypes of LN and studied renal tissues and cells to understand the effect of IFN in LN. Two hundred and twenty-one patients with systemic lupus erythematosus were studied. Serum IFN activity was measured by WISH bioassay. mRNA in situ hybridization was used in renal tissue to measure expression of the representative IFN-induced gene, IFN-induced protein with tetratricopeptide repeats-1 ( Class III/IV LN prevalence was significantly increased in patients with high serum IFN compared with those with low IFN (odds ratio 5.40, Systemic high IFN is involved in the pathogenesis of severe LN. We did not find colocalization of pDCs with IFN signature in renal tissue, and instead observed the greatest intensity of the IFN signature in glomerular areas, which could suggest a blood source of IFN.

Identifiants

DOI: 10.3899/jrheum.210391 PMID: 34782453 PMC: PMC8977285
pubmed: 34782453
pii: jrheum.210391
doi: 10.3899/jrheum.210391
pmc: PMC8977285
mid: NIHMS1754241
doi:

Substances chimiques

Antibodies, Antinuclear 0
CLEC4C protein, human 0
Interferon Type I 0
Lectins, C-Type 0
Membrane Glycoproteins 0
Receptors, Immunologic 0
anti-dsDNA autoantibody 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

388-397

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR057781
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR060861
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR065964
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR078416
Pays : United States

Informations de copyright

Copyright © 2022 by the Journal of Rheumatology.

Références

Rheumatology (Oxford). 2007 Apr;46(4):683-9
pubmed: 17132694
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
Arthritis Rheum. 2011 Apr;63(4):1044-53
pubmed: 21162028
Ann Rheum Dis. 2012 Mar;71(3):463-8
pubmed: 22088620
Transl Res. 2015 Feb;165(2):296-305
pubmed: 25468480
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Clin Rev Allergy Immunol. 2011 Feb;40(1):42-9
pubmed: 20063186
Am J Physiol Renal Physiol. 2010 Mar;298(3):F557-67
pubmed: 19955187
Arthritis Rheumatol. 2017 Oct;69(10):2006-2017
pubmed: 28891252
Arthritis Rheum. 2011 Jun;63(6):1681-8
pubmed: 21445962
Nat Commun. 2020 Dec 1;11(1):6149
pubmed: 33262343
Rheumatology (Oxford). 2011 Aug;50(8):1424-30
pubmed: 21415024
Science. 2001 Nov 16;294(5546):1540-3
pubmed: 11711679
Arthritis Rheum. 2006 Sep;54(9):2951-62
pubmed: 16947629
Rheumatology (Oxford). 2007 Jul;46(7):1052-6
pubmed: 17500073
Lupus. 2000;9(9):664-71
pubmed: 11199920
Expert Opin Investig Drugs. 2020 Sep;29(9):1025-1041
pubmed: 32700979
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Arthritis Rheum. 2010 Feb;62(2):553-61
pubmed: 20112359
Rheumatology (Oxford). 2016 Feb;55(2):252-62
pubmed: 26342222
Genes Immun. 2007 Sep;8(6):492-502
pubmed: 17581626
Clin Exp Immunol. 1987 Dec;70(3):562-9
pubmed: 2449306
J Am Soc Nephrol. 2004 Feb;15(2):241-50
pubmed: 14747370
Arthritis Rheum. 2008 Jul;58(7):2113-9
pubmed: 18576315
Nat Immunol. 2019 Jul;20(7):915-927
pubmed: 31110316
Arthritis Care Res (Hoboken). 2016 Feb;68(2):195-202
pubmed: 26213987
N Engl J Med. 2020 Jan 16;382(3):211-221
pubmed: 31851795
Curr Opin Immunol. 2020 Dec;67:87-94
pubmed: 33246136
Arthritis Res Ther. 2019 Apr 29;21(1):107
pubmed: 31036046
Science. 2003 May 23;300(5623):1298-300
pubmed: 12764198
Immunol Cell Biol. 2012 May;90(5):498-504
pubmed: 22430248
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Nat Immunol. 2007 May;8(5):487-96
pubmed: 17417641
Am J Med Sci. 2000 Aug;320(2):112-6
pubmed: 10981486
Arthritis Rheum. 2005 May;52(5):1491-503
pubmed: 15880830
Lupus. 2002;11(3):152-60
pubmed: 12004788
Arthritis Rheum. 2008 Aug;58(8):2481-7
pubmed: 18668568
Rheumatology (Oxford). 2014 Jul;53(7):1235-44
pubmed: 24599917
Arthritis Rheum. 2004 Jun;50(6):1861-72
pubmed: 15188363
Arthritis Rheum. 2006 Jun;54(6):1906-16
pubmed: 16736505

Auteurs

Taro Iwamoto (T)

T. Iwamoto, MD, PhD, Colton Center for Autoimmunity, New York University, New York, New York, USA, and Allergy and Clinical Immunology, Chiba University, Japan.
ORCID: 0000-0003-1663-3518

Jessica M Dorschner (JM)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Shanmugapriya Selvaraj (S)

S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA.

Valeria Mezzano (V)

S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA.

Mark A Jensen (MA)

M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA.

Danielle Vsetecka (D)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Shreyasee Amin (S)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Ashima Makol (A)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Thomas Osborn (T)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Kevin Moder (K)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Vaidehi R Chowdhary (VR)

J.M. Dorschner, BS, D. Vsetecka, MPH, S. Amin, MD, A. Makol, MD, T. Osborn, MD, K. Moder, MD, V.R. Chowdhary, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Peter Izmirly (P)

P. Izmirly, MD, H.M. Belmont, MD, Division of Rheumatology, New York University, New York, New York, USA.

H Michael Belmont (HM)

P. Izmirly, MD, H.M. Belmont, MD, Division of Rheumatology, New York University, New York, New York, USA.

Robert M Clancy (RM)

M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA.

Jill P Buyon (JP)

M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA.

Ming Wu (M)

S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA.

Cynthia A Loomis (CA)

S. Selvaraj, MS, V. Mezzano, MD, PhD, M. Wu, MD, C.A. Loomis, MD, PhD, Department of Pathology, New York University, New York, New York, USA.

Timothy B Niewold (TB)

M.A. Jensen, PhD, R.M. Clancy, PhD, J.P. Buyon, MD, T.B. Niewold, MD, Colton Center for Autoimmunity, New York University, New York, New York, USA; Timothy.Niewold@nyulangone.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Anticorps antinucléaires › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lectines › Lectines de type C › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Glomérulonéphrite lupique › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › High Systemic Type I Interferon Activity Is...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › High Systemic Type I Interferon Activity Is...